Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study

• Published in: PloS one Vol. 10; no. 11; p. e0140845
• Main Authors: Raben, D, Mocroft, A, Rayment, M, Mitsura, V M, Hadziosmanovic, V, Sthoeger, Z M, Palfreeman, A, Morris, S, Kutsyna, G, Vassilenko, A, Minton, J, Necsoi, C, Estrada, V P, Grzeszczuk, A, Johansson, V Svedhem, Begovac, J, Ong, E L C, Cabié, A, Ajana, F, Celesia, B M, Maltez, F, Kitchen, M, Comi, L, Dragsted, U B, Clumeck, N, Gatell, J, Gazzard, B, d'Arminio Monforte, A, Rockstroh, J, Yazdanpanah, Y, Champenois, K, Jakobsen, M L, Sullivan, A, Lundgren, J D
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 11-11-2015; Public Library of Science (PLoS)
• Subjects: Acquired immune deficiency syndrome; AIDS; AIDS Serodiagnosis - utilization; Audits; Candidiasis; Cervical cancer; Cervix; Diagnosis; Disease prevention; Drug therapy; Esophagus; Europe - epidemiology; Guidelines as Topic; Health behavior; Hepatitis; Hepatitis B; HIV; HIV Infections - diagnosis; HIV Infections - epidemiology; HIV testing; Hospitals; Human immunodeficiency virus; Humans; Infections; Infectious diseases; Lymphoma; Medical care; Medical diagnosis; Medical tests; Medicin och hälsovetenskap; Patients; Retrospective Studies; Surveillance; Surveys; Tuberculosis; Utilization; Zeidae; Europe; United Kingdom > UK; Belgium; Denmark; Italy; Belarus; France; Spain
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0140845

European guidelines recommend the routine offer of an HIV test in patients with a number of AIDS-defining and non-AIDS conditions believed to share an association with HIV; so called indicator conditions (IC). Adherence with this guidance across Europe is not known. We audited HIV testing behaviour in patients accessing care for a number of ICs. Participating centres reviewed the case notes of either 100 patients or of all consecutive patients in one year, presenting for each of the following ICs: tuberculosis, non-Hodgkins lymphoma, anal and cervical cancer, hepatitis B and C and oesophageal candidiasis. Observed HIV-positive rates were applied by region and IC to estimate the number of HIV diagnoses potentially missed. Outcomes examined were: HIV test rate (% of total patients with IC), HIV test accepted (% of tests performed/% of tests offered) and new HIV diagnosis rate (%). There were 49 audits from 23 centres, representing 7037 patients. The median test rate across audits was 72% (IQR 32-97), lowest in Northern Europe (median 44%, IQR 22-68%) and highest in Eastern Europe (median 99%, IQR 86-100). Uptake of testing was close to 100% in all regions. The median HIV+ rate was 0.9% (IQR 0.0-4.9), with 29 audits (60.4%) having an HIV+ rate >0.1%. After adjustment, there were no differences between regions of Europe in the proportion with >0.1% testing positive (global p = 0.14). A total of 113 patients tested HIV+. Applying the observed rates of testing HIV+ within individual ICs and regions to all persons presenting with an IC suggested that 105 diagnoses were potentially missed. Testing rates in well-established HIV ICs remained low across Europe, despite high prevalence rates, reflecting missed opportunities for earlier HIV diagnosis and care. Significant numbers may have had an opportunity for HIV diagnosis if all persons included in IC audits had been tested.